Technische Universität Dresden: Leukemia, Myeloid trials

The registry lists 14 Leukemia, Myeloid studies with Technische Universität Dresden as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
• Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AMLTerminatedNCT02229266Phase 2
• Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AMLCompletedNCT02140242Phase 3
• Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLCompletedNCT01830361Phase 2
• Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)CompletedNCT01462578Phase 2
• Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01295307Phase 2
• PET-CT in AML for Detection of Extramedullary AML ManifestationsCompletedNCT01278069
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
• Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeCompletedNCT00893373Phase 2
• Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)TerminatedNCT00720850Phase 2
• A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two GroupsCompletedNCT00521664Phase 3
• Registration of Children With CML and Treatment With ImatinibStatus unknownNCT00445822
• Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)CompletedNCT00422890Phase 3
• AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 YearsCompletedNCT00180102Phase 4